|Mr. Lewis G. Gradon||MD, CEO & Exec. Director||N/A||N/A||1961|
|Ms. Lyndal York||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Andrew Somervell||VP of Products & Technology||N/A||N/A||N/A|
|Hayden Brown||Investor Relations Mang.||N/A||N/A||N/A|
|Rachel Reynolds||Sr. Communications Mang.||N/A||N/A||N/A|
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems. It provides its products for use in respiratory care, acute care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and within the hospital. The company offers adult respiratory products, including AIRVO 2 system, a humidifier with integrated flow source; Optiflow, a nasal high flow therapy; and noninvasive and invasive ventilation systems. It also provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, accessories, and interfaces; and homecare products that include masks, CPAP devices, data management products, humidifiers, and accessories. It has operations in North America, Europe, the Asia Pacific, and internationally. The company was founded in 1934 and is headquartered in Auckland, New Zealand.
Fisher & Paykel Healthcare Corporation Limited’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 6; Compensation: 10.